It also killed Mycobacterium ulcerans lääkitys.

It also killed Mycobacterium ulcerans, a germ related to leprosy and tuberculosis that causes the flesh-eating disease Buruli This effect was first in 2002 lääkitys . Described by Line Brunet de Courssou, 05:30 humanitarian working in the Ivory Coast, the cured Buruli ulcer ulcers of the with daily applications of French clay she knew from childhood. Currently, advanced cases of Buruli be cured by surgical excision or amputation.

Search tone To Treat pathogenic bacteriakills French sound that different types of disease-causing bacteria is at the forefront of new research in ancient, nearly forgotten, but surprisingly strong healing. Among the bad bacteria French French sound turned out is to fight a flesh-eating bug studying healing clays under a two-year, 000 grant from the National Institutes of Health – National Center for Complementary and Alternative Medicine. Your ASU colleague Shelley Haydel lends her expertise in clinical medicine to perform the microbiological research. In 2002. Of years, people have used clay wounds wounds, relieve indigestion, and kill intestinal worms. Although the practice in the modern era has gone down, the recent rise of resistant germs has scientists looking to get closer to these ancient remedies exactly what they can do and how they do it. We start the first scientific evidence of why some minerals and other bacterial organisms could not possibly generate kill, said Williams.

Over POT-4POT-4 is a complement inhibitor which the complement of shut down activation cascade which could otherwise lead to local inflammation, tissue damage , and upregulation of angiogenic factors as vascular endothelial growth factor into the eye. Based on this mechanism of action, POT-4 holding the potential of effective to dry and wet Intel. 10-15 percent on AMD.

Potentia Pharmaceuticals an privately owned biotechnology companies developing drugs I data for the treatment which age-related macular degeneration , phase of last presented to the retina retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting of Atlanta, data were by the ASaP to clinical study for the lead drug candidate the currently in development in the treatment of AMD.